InvestorsHub Logo
Followers 9
Posts 480
Boards Moderated 0
Alias Born 12/17/2018

Re: None

Tuesday, 12/03/2019 8:46:04 PM

Tuesday, December 03, 2019 8:46:04 PM

Post# of 30463
An interesting under the radar event occured today. This further supports FDA enforcement discretion and ultimately regulations for CBD isolate products. This is a positive and key indicator for Canb, given their total focus is with pure CBD isolate products.

Canopy Growth officially entered the U.S. CBD market.

https://sports.yahoo.com/canopy-growth-quietly-unveils-new-cbd-line-for-us-consumers-175121239.html

I would anticipate that Canopy Growth would not move forward without a high level of confidence of positive enforcement discretion and regulation.

Also, we now have a $6-7 billion dollar company (Canopy) which has a piece of it owned by a $35 billion dollar company (Constellation Brands) which should have a significant lobbyist presence pushing government and the FDA for discretion of isolate.

What is even more interesting is this line is entirely "Hemp Derived Isolate".

https://www.firstandfree.com/en/shop

Now if pure CBD isolate was "garbage" and nobody wants it, and the FDA will not budge, then why would a $6 billion dollar company move forward with this venture?

This definitely bodes well for the future success of Canb.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CANB News